Stay updated with breaking news from Narcolepsy Type 1. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Elena Koundourakis, the head of the Orexin Franchise Development and Portfolio Strategy at Takeda, shares her thoughts on the recent positive topline results from a phase 2 trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.
New positive data on TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.
1. In this randomized controlled trial, an oral orexin receptor 2 (OX2R) agonist (TAK-994) was associated with improvements in wakefulness, sleepiness, and cataplexy incidence among patients with narcolepsy type 1. 2. TAK-994 was also associated with liver enzyme elevation and drug-induced hepatotoxicity. Evidence Rating Level: 1 (Excellent) Study Rundown: Narcolepsy is a rare chronic disorder